0

Succinobucol-eluting Stents Increase Neointimal Thickening and Peri-Strut Inflammation in a Porcine Coronary Model

Jonathan Watt, Simon Kennedy, Christopher McCormick, Ejaife O Agbani, Allan McPhaden, Alexander Mullen, Peter Czudaj, Boris Behnisch, Roger M Wadsworth, Keith G Oldroyd

Catheter Cardiovasc Interv. 2013 Mar;81(4):698-708.

PMID: 22581717

Abstract:

Objective:
The aim of this study was to assess the efficacy of stent-based delivery of succinobucol alone and in combination with rapamycin in a porcine coronary model.
Background:
Current drugs and polymers used to coat coronary stents remain suboptimal in terms of long term efficacy and safety. Succinobucol is a novel derivative of probucol with improved antioxidant and anti-inflammatory properties.
Methods:
Polymer-free Yukon stents were coated with 1% succinobucol (SucES), 2% rapamycin (RES), or 1% succinobucol plus 2% rapamycin solutions (SucRES) and compared with a bare metal stent (BMS).
Results:
The in vivo release profile of SucES indicated drug release up to 28 days (60% drug released at 7 days); 41 stents (BMS, n = 11; SucES, n =10; RES, n = 10; SucRES, n = 10) were implanted in the coronary arteries of 17 pigs. After 28 days, mean neointimal thickness was 0.31 ± 0.14 mm for BMS, 0.51 ± 0.14 mm for SucES, 0.19 ± 0.11 mm for RES, and 0.36 ± 0.17 mm for SucRES (P < 0.05 for SucES vs. BMS). SucES increased inflammation and fibrin deposition compared with BMS (P < 0.05), whereas RES reduced inflammation compared with BMS (P < 0.05).
Conclusion:
In this model, stent-based delivery of 1% succinobucol using a polymer-free stent platform increased neointimal formation and inflammation following coronary stenting.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR4245228 Succinobucol Succinobucol Price
qrcode